NSE: DRREDDY | BSE: 500124

Turnaround Potential

Download real time

1280.30 5.10 (0.40%)

High volume today

NSE 03 Dec, 2025 11:59 AM (IST)

106,856.6

Market Cap

High in industry

Beta 1Year

Very Low volatility

HC Ruling

Delhi HC reportedly allows Dr Reddy's to manufacture and export its weight-loss drug, Semaglutide See details

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

24 Jul 2025

1280.30

0.40%

Dr. Reddy's Laboratories (DRRD IN) Q1FY26 Result Update ...

Sell: Dr. Reddy's Laboratories Ltd.

Target

Prabhudas Lilladhar

Dr. Reddy's (DRRD) Q1FY26 EBITDA adjusted for licensing income was in line with our estimate. The base business margins and US sales ex of gRevlimid continued to remain weak. We have scale up base business margins from the current level of 15-16% to +21-22% in FY27E. Our FY26 and FY27E EPS broadly remain unchanged. DRRD have been investing cash flow from gRevlimid to build pipeline across peptides, biosimilars and GLP products; benefits of that may take some time. Further thin US pipeline in near term and competition in...

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

23 Jul 2025

1280.30

0.40%

Out-licensing income/lower R&D spend drive better-thanexpected EBITDA

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

Dr Reddy’s Labs (DRRD) reported sales in line with our estimates in 1QFY26, while EBITDA/PAT came in higher than expected, primarily led by higher outlicensing income and lower R&D expenses.

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

07 Jul 2025

1280.30

0.40%

DR. REDDY'S LABORATARIES

Sell: Dr. Reddy's Laboratories Ltd.

Geojit BNP Paribas

*over or under performance to benchmark index Dr. Reddy's Laboratories (Dr. Reddy's) is an Indian pharmaceuticals company that manufactures and markets more than 190 medications, 180+ active pharmaceutical...

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

12 May 2025

1280.30

0.40%

Dr. Reddy's Laboratories (DRRD IN) Q4FY25 Result Update ...

Sell: Dr. Reddy's Laboratories Ltd.

Target

Prabhudas Lilladhar

Dr. Reddy's (DRRD) Q4FY25 EBITDA was below our estimate. The base business margins and US sales ex of gRevlimid continued to remain weak. We have scale up base business margins from current level of 16% to +20% in FY27E. Our FY27E EPS stands cut by 4-5%. DRRD have been investing cash flow from gRevlimid to build pipeline across peptides, biosimilars and GLP products; benefits of that may take some time. Further thin US pipeline in near term and...

Dr. Reddy's Laboratories Ltd. is trading at high day volume of 3.6M.

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1280.30

0.40%

Result Update:Dr Reddys Labs

Buy: Dr. Reddy's Laboratories Ltd.

Target

Axis Direct

We maintain our BUY recommendation on the stock.

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1280.30

0.40%

Dr Reddys Labs (HOLD): NRT business to require huge marketing spend

Hold: Dr. Reddy's Laboratories Ltd.

BOB Capital Markets Ltd.

North America sales missed our estimates and reported US$ 395mn in 3QFY25 vs US$ 445mn in 2QFY25 impacted by gRevlimid

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1280.30

0.40%

Soft g-Revlimid sales, high expenses dent earnings

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

DRRD delivered in-line sales (adj. for NRT acquisition and milestone income) and marginally better operational performance in 3QFy25. Revenue/EBITDA YoY growth was moderate due to lower off-take of g-Revlimid and PSAI business, which was offset to some extent by healthy performance in the Russia market

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

24 Jan 2025

1280.30

0.40%

Core US business weakness coming to the fore

Sell: Dr. Reddy's Laboratories Ltd.

Target

Emkay

Adjusted for the milestone payment received from Journey Medical Corp, 3QFY25 EBITDA for Dr Reddy’s was below street/our estimates. The PAT miss was higher on account of lower other income.

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

06 Nov 2024

1280.30

0.40%

DR REDDY'S LABS

Sell: Dr. Reddy's Laboratories Ltd.

Prabhudas Lilladhar

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

06 Nov 2024

1280.30

0.40%

Decent print; work on growth levers underway

Hold: Dr. Reddy's Laboratories Ltd.

ICICI Securities Limited

Dr. Reddy’s Laboratories’ (DRL) Q2FY25 performance, adjusted for acquisition-related expenses (INR 561mn) and impairment charge of gNuvaring (INR 924mn), was ahead of our expectations

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Is Dr. Reddy's Laboratories Ltd. worth buying?

538 Votes:

Buy 77.88%

Sell 12.64%

Hold 9.48%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf